-
公开(公告)号：US11732053B2
公开(公告)日：2023-08-22
申请号：US17061219
申请日：2020-10-01
Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventor： Paul S. Frenette , Sandra Pinho , Qiaozhi Wei
IPC: A61K39/395 , A61K39/00 , C07K16/00 , C07K16/46 , C07K16/30 , C07K16/18 , C07K16/28 , A61P35/02 , A61K45/06
CPC classification number: C07K16/3061 , A61K39/3955 , A61P35/02 , C07K16/18 , C07K16/2821 , C07K16/2836 , C07K16/2878 , A61K45/06 , A61K2039/505 , C07K2317/76 , A61K39/3955 , A61K2300/00
Abstract: Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.
-
公开(公告)号：US20230250151A1
公开(公告)日：2023-08-10
申请号：US18079302
申请日：2022-12-12
Inventor： Marco Davila
IPC: C07K14/725 , C12N5/0783 , A61P35/02 , C12N15/62 , C07K16/28 , C12N5/00 , A61K47/65 , C12N15/85 , A61K35/17
CPC classification number: C07K14/7051 , C12N5/0636 , A61P35/02 , C12N15/62 , C07K16/2818 , C12N5/0075 , A61K47/65 , C12N15/85 , A61K35/17 , C07K16/2809 , C07K2317/622 , C07K2319/03
Abstract: Disclosed herein are methods of producing chimeric antigen receptor (CAR) T cells using substrates, such as artificial antigen presenting cells, containing on a surface a a heparin binding domain (HBD), anti-CD3 single chain antibodies, anti-CD28 single chain antibodies (scFv), and optionally anti-41BBL antibodies. Anti-CD3 and Anti-CD28 scFvs bind and activate expanding T cells ex vivo, while the Heparin Binding Domain binds the viral vector, thereby bringing the T cells into close proximity with virus for effective gene transfer. This is a less costly, renewable, modifiable, and efficacious alternative to coated beads and RetroNectin® for gene transfer.
-
公开(公告)号：US20230250150A1
公开(公告)日：2023-08-10
申请号：US18058707
申请日：2022-11-23
Applicant: The General Hospital Corporation
Inventor： Marcela V. Maus , Mark Cobbold , Irene Scarfo
IPC: C07K14/725 , A61P37/06 , A61P35/02 , A61P35/00 , A61K35/17 , C07K14/705 , C07K16/28 , C12N5/0783
CPC classification number: C07K14/7051 , A61P37/06 , A61P35/02 , A61P35/00 , A61K35/17 , C07K14/70517 , C07K14/70578 , C07K16/2896 , C12N5/0636 , A61K38/00
Abstract: Described herein are methods for producing and utilizing an alternative signal 1 domain to construct an optimally signaling CAR. Alternative signal 1 domains of the present technology are based on alternatives to CD3ζ, including mutated ITAMs from CD3ζ (which contains 3 IT AM motifs), truncations of CD3ζ, and alternative splice variants known as CD3s, CD3 theta, and artificial constructs engineered to express fusions between CD3s or CD30 and CD3ζ. CAR polypeptides comprising alternative signal 1 domains are utilized to engineer CAR T cells. Further, this technology related to methods of treating cancer by administering to a subject in need thereof CAR T cells comprising alternative signal 1 domains.
-
114.发明公开
公开(公告)号：US20230242542A1
公开(公告)日：2023-08-03
申请号：US18118555
申请日：2023-03-07
Applicant: BEIGENE SWITZERLAND GMBH
Inventor： Zhiwei WANG , Yunhang GUO , Gongyin SHI , Lai WANG
IPC: C07D487/04 , A61P35/02 , A61P35/04
CPC classification number: C07D487/04 , A61P35/02 , A61P35/04 , C07B2200/13
Abstract: The present invention relates to pharmaceutical compositions comprising (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for the treatment of B-cell malignancies.
![COMPOSITIONS COMPRISING (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE](/docs/US/2023-08-03/US20230242542A1/abs.jpg.600x600.jpg)
-
115.发明公开
公开(公告)号：US20230242533A9
公开(公告)日：2023-08-03
申请号：US17618362
申请日：2020-06-24
Applicant: IMPACT THERAPEUTICS (SHANGHAI), INC
Inventor： Suixiong CAI , Ye Edward TIAN , Xiaozhu WANG
IPC: C07D487/04 , A61K31/5377 , A61K45/06 , C07D519/00 , A61P35/00 , A61P35/02
CPC classification number: C07D487/04 , A61K31/5377 , A61K45/06 , C07D519/00 , A61P35/00 , A61P35/02
Abstract: The disclosure provides novel substituted fused heteroaromatic compounds as represented in Formula I, wherein A1-A6 and R1-R4 are defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inhibitors. Therefore, the compounds of the disclosure may be used to treat ATR-mediated diseases, disorders and conditions, such as cancer.
-
116.发明公开
公开(公告)号：US20230241112A1
公开(公告)日：2023-08-03
申请号：US18170690
申请日：2023-02-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
117.发明公开
公开(公告)号：US20230241109A1
公开(公告)日：2023-08-03
申请号：US18164413
申请日：2023-02-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20230241103A1
公开(公告)日：2023-08-03
申请号：US17820724
申请日：2022-08-18
Applicant: Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventor： Rimas J. Orentas , Dina Schneider , Boro Dropulic , Dimiter S. Dimitrov , Zhongyu Zhu
IPC: A61K35/17 , C07K14/725 , C07K14/705 , C07K16/28 , A61P35/02 , A61K39/395 , A61K48/00
CPC classification number: A61K35/17 , C07K14/7051 , C07K14/70517 , C07K16/2803 , A61P35/02 , A61K39/39558 , A61K48/0016 , A61K2039/505
Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20230235406A1
公开(公告)日：2023-07-27
申请号：US17903700
申请日：2022-09-06
Applicant: Onyx Therapeutics, Inc.
Inventor： Brian TUCH , Jeremiah DEGENHARDT , Andrea LOEHR , Kevin KWEI , Christopher J. KIRK
IPC: C12Q1/6886 , A61P35/02 , A61K31/69 , A61K38/05 , A61K38/07 , A61K31/145 , A61K38/06 , G01N33/574
CPC classification number: C12Q1/6886 , A61P35/02 , A61K31/69 , A61K38/05 , A61K38/07 , A61K31/145 , A61K38/06 , G01N33/57492 , C12Q2600/106 , C12Q2600/158 , G01N2333/70535
Abstract: Methods of treating a tumor in a subject and methods of determining a treatment regimen for a subject with a tumor are provided herein. In exemplary aspects, the methods comprise measuring the level of expression of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof. In exemplary aspects, the subject is a subject from which a sample was obtained, wherein the level of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof, has been measured from the sample. Related kits, computer readable-storage media, systems, and methods implemented by a processor in a computer are further provided.
-
公开(公告)号：US11702450B2
公开(公告)日：2023-07-18
申请号：US17267914
申请日：2019-08-28
Applicant: UNIVERSITÉ DE MONTRÉAL
Inventor： Céline Laumont , Pierre Thibault , Sébastien Lemieux , Claude Perreault
CPC classification number: C07K7/06 , A61P35/02 , C07K14/70539 , A61K38/00
Abstract: T cells, notably CD8 T cells, are known to be essential players in tumor eradication as the presence of tumor-infiltrating lymphocytes (TILS) in several cancers positively correlates with a good prognosis. To eliminate tumor cells, CD8 T cells recognize tumor antigens, which are MHC I-associated peptides present at the surface of tumor cells, with no or very low expression on normal cells. Described herein a proteogenomic approach using RNA-sequencing data from cancer and normal-matched mTEChi samples in order to identify non-tolerogenic tumor-specific antigens derived from (i) coding and non-coding regions of the genome, (ii) non-synonymous single-base mutations or short insertion/deletions and more complex rearrangements as well as (iii) endogenous retroelements, which works regardless of the sample's mutational load or complexity.
